Literature DB >> 9355786

Enkephalins and enkephalinase inhibitors in intestinal fluid and electrolyte transport.

J Turvill1, M Farthing.   

Abstract

Opioids have long been known to inhibit intestinal fluid and electrolyte secretion. They act locally on central and peripheral opiate receptors where they are rapidly degraded by neuropeptidases, the major one being enkephalinase (EC 3.4.24.11). A number of studies have shown that, when the problem of degradation can be overcome, enkephalins have potent antisecretory properties. In 1980, an enkephalinase inhibitor was described which increased the functional availability of enkephalins. More recently an orally active enkephalinase inhibitor, acetorphan, has been shown to inhibit infectious and chemically induced diarrhoea. Acetorphan does not appear to affect gastrointestinal motility and, although it also inhibits the breakdown of a range of other neuropeptides, such as substance P and neuropeptide Y, it is a promising agent with therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355786     DOI: 10.1097/00042737-199709000-00010

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  10 in total

Review 1.  Novel targets for the control of secretory diarrhoea.

Authors:  M J G Farthing
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Management of infectious diarrhoea.

Authors:  A C Casburn-Jones; M J G Farthing
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 3.  Racecadotril.

Authors:  A J Matheson; S Noble
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 4.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

5.  Serotonin and vasoactive intestinal peptide antagonists attenuate rotavirus diarrhoea.

Authors:  S Kordasti; H Sjövall; O Lundgren; L Svensson
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

6.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

7.  Pharmacologic Comparison of Clinical Neutral Endopeptidase Inhibitors in a Rat Model of Acute Secretory Diarrhea.

Authors:  David W Griggs; Michael J Prinsen; Jonathan Oliva; Mary A Campbell; Stacy D Arnett; Deena Tajfirouz; Peter G Ruminski; Ying Yu; Brian R Bond; Yuhua Ji; Georg Neckermann; Robert K M Choy; Eugenio de Hostos; Marvin J Meyers
Journal:  J Pharmacol Exp Ther       Date:  2016-02-23       Impact factor: 4.030

Review 8.  A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults.

Authors:  Wolfgang Fischbach; Viola Andresen; Marion Eberlin; Tobias Mueck; Peter Layer
Journal:  Front Med (Lausanne)       Date:  2016-10-14

Review 9.  The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review.

Authors:  MahmoudReza Khansari; MasourReza Sohrabi; Farhad Zamani
Journal:  Middle East J Dig Dis       Date:  2013-01

Review 10.  Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials.

Authors:  Marion Eberlin; Min Chen; Tobias Mueck; Jan Däbritz
Journal:  BMC Pediatr       Date:  2018-04-03       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.